Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
regulator Processed

Vinay Prasad & Moderna

8 shared events · Importance 3 · Last updated Feb 19, 2026

Importance
3
Shared Events
8
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard

Vinay Prasad, in his capacity as the former Director of the FDA's Center for Biologics Evaluation and Research (CBER), acted as a regulator of Moderna, notably refusing to review their flu vaccine application in February 2026 due to concerns about the study design.

77
Regulatory
Vinay Prasad: Dr. Vinay Prasad, a former top United States — Food and Drug Administration official, initially blocked Moderna's application, raising concerns about the comparator vaccine used in trials. His actions highlighted heightened scrutiny but were ultimately challenged and overturned.
Moderna: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.
Jun 18, 2026 · 28 articles
71
Regulatory
Vinay Prasad: Prasad's refusal-to-file decision was reversed, and he later left the FDA; his actions highlighted regulatory tensions.
Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.
Aug 05, 2026 · 105 articles
20
Domestic
Vinay Prasad: Prasad, former FDA vaccine chief, departed in April. His exit is part of the agency's instability.
Moderna: Moderna, a vaccine maker, had disagreements with the FDA. Overton's vaccine stance may affect future approvals.
Aug 19, 2026 · 101 articles
0
Regulatory
Vinay Prasad: As a top deputy at the United States — Food and Drug Administration, Vinay Prasad co-authored the New England Journal of Medicine piece announcing the change in drug approval requirements. However, he has also taken a more restrictive approach to vaccines and gene therapies, creating some inconsistency.
Feb 18, 2026 · 6 articles
0
Regulatory
Vinay Prasad: Dr. Vinay Prasad, the United States — Food and Drug Administration vaccine director, issued the refusal-to-file letter to Moderna, citing issues with its clinical trial methodology.
Feb 10, 2026 · 6 articles
0
Regulatory
Vinay Prasad: Dr. Vinay Prasad, director of the United States — Food and Drug Administration's Center for Biologics Evaluation and Research, initially overruled agency reviewers and signed the refusal letter for Moderna's vaccine application, citing concerns about the trial's control arm.
Feb 18, 2026 · 9 articles
0
Domestic
Vinay Prasad: Vinay Prasad>>>, a close ally of Marty Makary>>>, served as the FDA's vaccine and biotech chief but was pushed out twice, contributing to the agency's internal dysfunction and leadership instability.
May 08, 2026 · 114 articles
0
Business
Vinay Prasad: Vinay Prasad, the United States — Food and Drug Administration's vaccine chief who advocated for placebo-controlled trials, is leaving the agency, which might influence future regulatory approaches.
Apr 01, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Vinay Prasad and Moderna interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.